Option Care Health shares fell 25.5% after first quarter results, as investors reacted to a revenue growth deceleration and a downward revision to full-year revenue guidance stemming from an unexpected drop in the chronic therapy patient census and delayed program launches.

• Reported revenue growth of just 1% for Q1, below company expectations, with chronic therapy revenues declining year-over-year.
• Acute therapy portfolio delivered high single-digit revenue growth, outperforming market growth rates.
• Chronic portfolio faced headwinds including a "significantly higher" number of patients affected by insurance changes, causing patient census to fall more than anticipated and leading to a less favorable therapy mix.
• Guidance for full-year revenue was revised down due to more challenging industry dynamics, regulatory or commercial delays in rare/orphan portfolio launches, and slower-than-expected growth in specialty therapies.
• Management is reallocating resources, increasing commercial team size, and refocusing growth initiatives in response to these challenges.